What is HC Wainwright’s Estimate for MediciNova Q1 Earnings?

MediciNova, Inc. (NASDAQ:MNOV) – Analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of MediciNova in a report released on Monday, March 16th. HC Wainwright analyst L. Egana-Gorrono expects that the biopharmaceutical company will post earnings per share of ($0.06) for the quarter. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for MediciNova’s current full-year earnings is ($0.24) per share. HC Wainwright also issued estimates for MediciNova’s Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.06) EPS, Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($0.26) EPS, FY2027 earnings at ($0.43) EPS, FY2028 earnings at $0.29 EPS, FY2029 earnings at $1.90 EPS and FY2030 earnings at $3.02 EPS.

A number of other research analysts also recently commented on the company. D. Boral Capital reiterated a “buy” rating and issued a $9.00 price objective on shares of MediciNova in a report on Friday, January 30th. Lucid Cap Mkts upgraded MediciNova to a “strong-buy” rating in a research note on Monday, January 5th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MediciNova in a report on Monday, December 29th. Two investment analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, MediciNova has a consensus rating of “Moderate Buy” and an average target price of $8.00.

MediciNova Price Performance

Shares of NASDAQ MNOV opened at $1.41 on Wednesday. The company has a market capitalization of $69.40 million, a price-to-earnings ratio of -5.87 and a beta of 0.58. The business has a 50-day moving average of $1.54 and a two-hundred day moving average of $1.42. MediciNova has a 1 year low of $1.13 and a 1 year high of $1.96.

MediciNova (NASDAQ:MNOV) last issued its earnings results on Friday, February 20th. The biopharmaceutical company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.05. The firm had revenue of $0.15 million for the quarter.

Hedge Funds Weigh In On MediciNova

Several hedge funds have recently made changes to their positions in MNOV. Jane Street Group LLC purchased a new stake in shares of MediciNova in the 4th quarter valued at about $214,000. Citadel Advisors LLC purchased a new position in MediciNova during the 3rd quarter worth approximately $92,000. Goldman Sachs Group Inc. acquired a new position in MediciNova during the fourth quarter worth approximately $35,000. StoneX Group Inc. acquired a new position in MediciNova during the fourth quarter worth approximately $25,000. Finally, State Street Corp lifted its stake in MediciNova by 10.9% in the fourth quarter. State Street Corp now owns 193,698 shares of the biopharmaceutical company’s stock valued at $254,000 after buying an additional 19,100 shares during the last quarter. Hedge funds and other institutional investors own 9.90% of the company’s stock.

MediciNova News Roundup

Here are the key news stories impacting MediciNova this week:

• Positive Sentiment: HC Wainwright initiated coverage with a “Buy” rating and a $10 price target, a material bullish endorsement for a small-cap biotech that can attract new investor attention and trading interest. HC Wainwright Initiates Coverage on MediciNova (NASDAQ:MNOV)
• Positive Sentiment: The analyst model projects multi-year upside: HC Wainwright’s forecasts show MediciNova moving from near-term losses to profitability (projected EPS of $0.29 in FY2028, $1.90 in FY2029 and $3.02 in FY2030). That long-term earnings runway supports the high $10 target and could justify speculative buying by growth-oriented investors. HC Wainwright & Co. initiates coverage of MediciNova (MNOV) with buy recommendation
• Neutral Sentiment: HC Wainwright’s near-term quarterly estimates remain negative (Q1–Q3 2026: ~$0.06 loss per share; Q4 2026: ~$0.08 loss), and FY2026 is modeled at a loss — meaning any upside depends on successful execution and clinical/commercial progress rather than immediate earnings improvement.
• Negative Sentiment: Despite the bullish initiation, the stock is down today—likely reflecting that the market is weighing near-term negative EPS, small market cap/liquidity and skepticism over execution risk before the multi-year upside can be realized. Volume is modest and technicals (50/200-day moving averages near the current price) suggest limited conviction so far.

MediciNova Company Profile

MediciNova, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel small-molecule therapeutics for neurodegenerative, inflammatory, fibrotic and oncological diseases. Founded in the late 1990s, the company advances its proprietary compounds through clinical trials and strategic partnerships, with a goal of addressing areas of high unmet medical need. MediciNova is headquartered in San Diego, California, and maintains a presence in Tokyo to support collaborations and regulatory interactions in Asian markets.

The company’s leading clinical asset, MN-166 (ibudilast), is an anti-inflammatory and neuroprotective agent originally approved in Japan for asthma and post-stroke dizziness.